Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance | Zendy

Tang Liu | Zendy; Zhihong Li | Zendy; Qing Zhang | Zendy; Karen De Amorim Bernstein | Zendy; Santiago A. LozanoCalderón | Zendy; Edwin Choy | Zendy; Francis J. Hornicek | Zendy; Zhenfeng Duan | Zendy

Open Access

Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance

Author(s) -

Tang Liu,

Zhihong Li,

Qing Zhang,

Karen De Amorim Bernstein,

Santiago A. LozanoCalderón,

Edwin Choy,

Francis J. Hornicek,

Zhenfeng Duan

Publication year - 2016

Publication title -

oncotarget

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.373

H-Index - 127

ISSN - 1949-2553

DOI - 10.18632/oncotarget.13148

Subject(s) - osteosarcoma , crispr , medicine , drug resistance , doxorubicin , p glycoprotein , multiple drug resistance , cancer research , chemotherapy , pharmacology , gene , biology , genetics

Multi-drug resistance (MDR) remains a significant obstacle to successful chemotherapy treatment for osteosarcoma patients. One of the central causes of MDR is the overexpression of the membrane bound drug transporter protein P-glycoprotein (P-gp), which is the protein product of the MDR gene ABCB1. Though several methods have been reported to reverse MDR in vitro and in vivo when combined with anticancer drugs, they have yet to be proven useful in the clinical setting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research